S100A4 expression is associated with lymph node metastasis in papillary microcarcinoma of the thyroid

Modern Pathology

Volumn 21, Issue 6, 2008, Pages 748-755

  Min, Hye Sook ^a   Choe, Gheeyoung ^b,c   Kim, Sung Won ^b,c   Park, Young Joo ^b,c   Park, Do Joon ^c   Youn, Yeo Kyu ^c   Park, Seong Hoe ^c   Cho, Bo Youn ^c   Park, So Yeon ^b,c  

^a National Cancer Center   (South Korea)

^b Seoul National University Bundang Hospital   (South Korea)

^c Seoul National University College of Medicine   (South Korea)

Author keywords

Lymph node; Metastasis; Papillary microcarcinoma; S100A4; Thyroid

Indexed keywords

B RAF KINASE; CALVASCULIN; CYCLIN D1; MUCIN 1; PROTEIN P27;

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER DIAGNOSIS; CLINICAL FEATURE; CONTROLLED STUDY; FEMALE; GENE MUTATION; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; THYROID CARCINOMA; THYROID PAPILLARY MICROCARCINOMA; TUMOR VOLUME;

ADENOCARCINOMA, PAPILLARY; CA-15-3 ANTIGEN; CYCLIN D1; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; MUTATION; POLYMERASE CHAIN REACTION; PROGNOSIS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROTO-ONCOGENE PROTEINS B-RAF; S100 PROTEINS; THYROID NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 44349136822     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2008.51     Document Type: Article

References (35)

1. LiVolsi VA, Albores-Saavedra J, Asa SL, et al. Papillary carcinoma In: DeLellis RA, Lloyd RV, Heitz PU, Eng C (eds). World Health Organization Classification of Tumors: Pathology and Genetics of Tumors of Endocrine Organs. IARC Press: Lyon, 2004, pp 57-66.
2. Roti E, Rossi R, Trasforini G, et al. Clinical and histological characteristics of papillary thyroid microcarcinoma: results of a retrospective study in 243 patients. J Clin Endocrinol Metab 2006;91:2171-2178.
3. Lee J, Rhee Y, Lee S, et al. Frequent, aggressive behaviors of thyroid microcarcinomas in korean patients. Endocr J 2006;53:627-632.
4. Cheema Y, Olson S, Elson D, et al. What is the biology and optimal treatment for papillary microcarcinoma of the thyroid? J Surg Res 2006;134:160-162.
5. Hay ID, Grant CS, van Heerden JA, et al. Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 1992;112:1139-1146.
6. Baudin E, Travagli JP, Ropers J, et al. Microcarcinoma of the thyroid gland: the Gustave-Roussy Institute experience. Cancer 1998;83:553-559.
7. Yamashita H, Noguchi S, Murakami N, et al. Extracapsular invasion of lymph node metastasis. A good indicator of disease recurrence and poor prognosis in patients with thyroid microcarcinoma. Cancer 1999;86:842-849.
8. Schlumberger MJ. Papillary and follicular thyroid carcinoma. N Engl J Med 1998;338:297-306.
9. Sugitani I, Fujimoto Y. Symptomatic vs asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. Endocr J 1999;46:209-216.
10. Chow SM, Law SC, Chan JK, et al. Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. Cancer 2003;98:31-40.
11. Pellegriti G, Scollo C, Lumera G, et al. Clinical behavior and outcome of papillary thyroid cancers smaller than 1.5cm in diameter: study of 299 cases. J Clin Endocrinol Metab 2004;89:3713-3720.
12. Greene FL, Page DL, Fleming ID, et al. (eds). AJCC Cancer Staging Manual, 6th edn. Springer: New York, 2002.
13. Khoo ML, Beasley NJ, Ezzat S, et al. Overexpression of cyclin D1 and underexpression of p27 predict lymph node metastases in papillary thyroid carcinoma. J Clin Endocrinol Metab 2002;87:1814-1818.
14. Zou M, Al-Baradie RS, Al-Hindi H, et al. S100A4 (Mts1) gene overexpression is associated with invasion and metastasis of papillary thyroid carcinoma. Br J Cancer 2005;93:1277-1284.
15. Wreesmann VB, Sieczka EM, Socci ND, et al. Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 2004;64:3780-3789.
16. Karlidag T, Cobanoglu B, Keles E, et al. Expression of Bax, p53, and p27/kip in patients with papillary thyroid carcinoma with or without cervical nodal metastasis. Am J Otolaryngol 2007;28:31-36.
17. Xing M, Westra WH, Tufano RP, et al. BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 2005;90:6373-6379.
18. Trovisco V, Soares P, Sobrinho-Simoes M. B-RAF mutations in the etiopathogenesis, diagnosis, and prognosis of thyroid carcinomas. Hum Pathol 2006;37:781-786.
19. Khoo ML, Freeman JL, Witterick IJ, et al. Under-expression of p27/Kip in thyroid papillary microcarcinomas with gross metastatic disease. Arch Otolaryngol Head Neck Surg 2002;128:253-257.
20. Khoo ML, Ezzat S, Freeman JL, et al. Cyclin D1 protein expression predicts metastatic behavior in thyroid papillary microcarcinomas but is not associated with gene amplification. J Clin Endocrinol Metab 2002;87:1810-1813.
21. Ito Y, Uruno T, Takamura Y, et al. Papillary microcarcinomas of the thyroid with preoperatively detectable lymph node metastasis show significantly higher aggressive characteristics on immunohistochemical examination. Oncology 2005;68:87-96.
22. Gemsenjäger E, Perren A, Seifert B, et al. Lymph node surgery in papillary thyroid carcinoma. J Am Coll Surg 2003;197:182-190.
23. Ito Y, Tomoda C, Uruno T, et al. Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. World J Surg 2004;28:498-501.
24. Cappelli C, Castellano M, Braga M, et al. Aggressiveness and outcome of papillary thyroid carcinoma (PTC) vs microcarcinoma (PMC): a mono-institutional experience. J Surg Oncol 2007;95:555-560.
25. Garrett SC, Varney KM, Weber DJ, et al. S100A4, a mediator of metastasis. J Biol Chem 2006;281:677-680.
26. Helfman DM, Kim EJ, Lukanidin E, et al. The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer 2005;92:1955-1958.
27. Mazzucchelli L. Protein S100A4: too long overlooked by pathologists? Am J Pathol 2002;160:7-13.
28. Zou M, Famulski KS, Parhar RS, et al. Microarray analysis of metastasis-associated gene expression profiling in a murine model of thyroid carcinoma pulmonary metastasis: identification of S100A4 (Mts1) gene overexpression as a poor prognostic marker for thyroid carcinoma. J Clin Endocrinol Metab 2004;89:6146-6154.
29. Liu W, Wei W, Winer D, et al. CEACAM1 impedes thyroid cancer growth but promotes invasiveness: a putative mechanism for early metastases. Oncogene 2007;26:2747-2758.
30. Ito Y, Yoshida H, Tomoda C, et al. S100A4 expression is an early event of papillary carcinoma of the thyroid. Oncology 2004;67:397-402.
31. Namba H, Nakashima M, Hayashi T, et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab 2003;88:4393-4397.
32. Nikiforova MN, Kimura ET, Gandhi M, et al. BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas. J Clin Endocrinol Metab 2003;88:5399-5404.
33. Fugazzola L, Mannavola D, Cirello V, et al. BRAF mutations in an Italian cohort of thyroid cancers. Clin Endocrinol (Oxf) 2004;61:239-243.
34. Kim TY, Kim WB, Song JY, et al. The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf) 2005;63:588-593.
35. Wojciechowska K, Lewinski A. BRAF mutations in papillary thyroid carcinoma. Endocr Regul 2006;40:129-138.